Journalist

Kim Dong-young
Kim Dong-young김동영
ReporterSamsung Biologics, CJ CheilJedang, LG Chem, Celltrion, Naver, Krafton, Nexon, Hyundai Mobis etc. & energy, game, food, bio, petrochemical, AI
Kim Dong-young is a bilingual journalist at AJU Press (AJP), covering Korean tech, energy, and bio/pharma.
He reports from the field at events like CES and APEC, runs AJP's YouTube channels,
and is pursuing a master's at Sogang's MOT program. "I try everything in this AI era that can improve yet preserve the facts. Journalism still serves as my core."
[CES 2026] South Korea fields 853 companies,  3rd largest presence [[CES 2026]] South Korea fields 853 companies, 3rd largest presence

[[CES 2026]] South Korea fields 853 companies, 3rd largest presence

Chinas robotics supremacy set for full display at CES 2026 China's robotics supremacy set for full display at CES 2026

China's robotics supremacy set for full display at CES 2026

South Korea to launch Asia-Pacifics first AI Basic Law on Jan. 22 South Korea to launch Asia-Pacific's first AI Basic Law on Jan. 22

South Korea to launch Asia-Pacific's first AI Basic Law on Jan. 22

Celltrion forecasts record quarterly revenue, operating profit for Q4 Celltrion forecasts record quarterly revenue, operating profit for Q4

Celltrion forecasts record quarterly revenue, operating profit for Q4

Navers new AI model ranks second among Korean models in global benchmark Naver's new AI model ranks second among Korean models in global benchmark

Naver's new AI model ranks second among Korean models in global benchmark

Nota to supply AI optimization tech for Samsungs next-gen Exynos 2600 chip Nota to supply AI optimization tech for Samsung's next-gen Exynos 2600 chip

Nota to supply AI optimization tech for Samsung's next-gen Exynos 2600 chip

Home robots take center stage as Korea leads physical AI push at CES 2026 Home robots take center stage as Korea leads physical AI push at CES 2026

Home robots take center stage as Korea leads physical AI push at CES 2026

Celltrion wins FDA nod for phase 1 trial of bispecific antibody cancer drug Celltrion wins FDA nod for phase 1 trial of bispecific antibody cancer drug

Celltrion wins FDA nod for phase 1 trial of bispecific antibody cancer drug

Korea Zinc clears legal hurdle for $7.4 billion U.S. smelter project Korea Zinc clears legal hurdle for $7.4 billion U.S. smelter project

Korea Zinc clears legal hurdle for $7.4 billion U.S. smelter project

Hate it or not, Coupang remains indispensable to Korean consumers — for now Hate it or not, Coupang remains indispensable to Korean consumers — for now

Hate it or not, Coupang remains indispensable to Korean consumers — for now